RARE DISEASERESEARCH ATLAS

ORPHA:30925

Hereditary arginine vasopressin deficiency

low confidenceSubtype of disorder

Also known as: Hereditary CDI · Hereditary neurogenic diabetes insipidus

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

1,543

Trials

10

Interventional, condition-specific

Researchers

945

Distinct authors in sample

Gene link

AVP

Strong

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

central diabetes insipidus is a rare genetic subtype of central diabetes insipidus (CDI) characterized by polyuria and polydipsia due to a deficiency in vasopressin (AVP) synthesis.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (9)

ADH deficiency · AVP deficiency · Arginine vasopressin deficiency · antidiuretic hormone deficiency · diabetes insipidus of pituitary gland · hereditary CDI · hereditary neurogenic diabetes insipidus · pituitary gland diabetes insipidus · vasopressin deficiency

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Strong — AVP

  2. LiteraturePresent

    1,543 matched papers (1,083 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    10 matched on ClinicalTrials.gov (7 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (AVP).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

1,543

1,543 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

1,543 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

1,083 in the last 10 years · low confidence

Phrase hits: 1,543 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

945

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Christ-Crain M17 papers · 2026

    Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland. mirjam.christ-crain@usb.ch.

    Papers in Europe PMC
  2. 02
    Atila C13 papers · 2026

    Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.

    Papers in Europe PMC
  3. 03
    Refardt J10 papers · 2026

    Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.

    Papers in Europe PMC
  4. 04
    Müller HL5 papers · 2026

    Department of Pediatrics and Pediatric Hematology/Oncology, University Children's Hospital, Carl von Ossietzky Universität Oldenburg, Klinikum Oldenburg AöR, Oldenburg, Germany.

    Papers in Europe PMC
  5. 05
    Pala A5 papers · 2026

    Department of Neurosurgery, Ulm University, Ulm, Germany.

    Papers in Europe PMC
  6. 06
    Urano F5 papers · 2026
    Papers in Europe PMC
  7. 07
    Chifu I4 papers · 2025

    Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, Wurzburg, Germany.

    Papers in Europe PMC
  8. 08
    Fassnacht M4 papers · 2025

    Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Wuerzburg, Wurzburg, Germany.

    Papers in Europe PMC
  9. 09
    Ferrante E4 papers · 2026

    Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

    Papers in Europe PMC
  10. 10
    van Santen HM4 papers · 2026

    Department of Pediatric Endocrinology, Wilhelmina Children's Hospital, UMC Utrecht, Utrecht, the Netherlands.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

10

interventional trials for this specific condition

10 interventional trials matched this specific condition name; 7 currently recruiting in our sample.

Data as of 27 July 2026

10 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 91.7th percentile).

low confidence · 91.7th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

10 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

None of the matched observational studies is currently listed as recruiting.

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Hereditary arginine vasopressin deficiency" OR "Hereditary CDI" OR "Hereditary neurogenic diabetes insipidus" OR "ADH deficiency" OR "AVP deficiency" OR "Arginine vasopressin deficiency" OR "antidiuretic hormone deficiency" OR "diabetes insipidus of pituitary gland" OR "diabetes insipidus of the pituitary gland" OR "pituitary gland diabetes insipidus" OR "vasopressin deficiency"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Hereditary arginine vasopressin deficiency" OR "Hereditary CDI" OR "Hereditary neurogenic diabetes insipidus" OR "ADH deficiency" OR "AVP deficiency" OR "Arginine vasopressin deficiency" OR "antidiuretic hormone deficiency" OR "diabetes insipidus of pituitary gland" OR "diabetes insipidus of the pituitary gland" OR "pituitary gland diabetes insipidus" OR "vasopressin deficiency" OR "AVP"

Recall-expansion terms: AVP

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 10 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • "Arginine vasopressin deficiency" also appears on ORPHA:178029
  • Publication count (1543) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-26T23:26:18.424Z